[1]祝亚军.高危型HPV-DNA及TCT检测筛查宫颈癌及宫颈癌前病变的价值[J].医学信息,2019,32(22):157-159.[doi:10.3969/j.issn.1006-1959.2019.22.054]
 ZHU Ya-jun.The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions[J].Journal of Medical Information,2019,32(22):157-159.[doi:10.3969/j.issn.1006-1959.2019.22.054]
点击复制

高危型HPV-DNA及TCT检测筛查宫颈癌及宫颈癌前病变的价值()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年22期
页码:
157-159
栏目:
诊疗技术
出版日期:
2019-11-15

文章信息/Info

Title:
The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions
文章编号:
1006-1959(2019)22-0157-03
作者:
祝亚军
(鹰潭市妇幼保健院检验科,江西 鹰潭 335000)
Author(s):
ZHU Ya-jun
(Department of Clinical Laboratory,Yingtan Maternal and Child Health Hospital,Yingtan 335000,Jiangxi,China)
关键词:
宫颈癌宫颈癌前病变HPV-DNATCT
Keywords:
Cervical carcinomaCervical precancerous lesionsHPV-DNATCT
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2019.22.054
文献标志码:
A
摘要:
目的 研究高危型人乳头瘤病毒-DNA(HPV-DNA)及液基薄层细胞检测系统(TCT)检测筛查宫颈癌及宫颈癌前病变的价值。方法 选择2016年3月~2019年2月本院收治的宫颈病变患者200例,所有患者均行高危型HPV-DNA检测、TCT检查,先行高危型HPV-DNA和TCT单项检测,再行联合检测:T1(先高危型HPV-DNA,再TCT)、T2(先TCT,再高危型HPV-DNA)。随访记录其病理检查结果,以病理检查结果为“金标准”,评估各检测方法的敏感性、特异性、准确度。结果 本研究中经组织病理学检查证实阴性168例(慢性宫颈炎),阳性32例(CINⅠ级及以上),其中CINⅠ16例,CINⅡ~Ⅲ15例,浸润性癌1例;高危型HPV-DNA检测宫颈癌前病变及宫颈癌的敏感性高于TCT、T2,特异性、准确度低于TCT、T2、T1,差异有统计学意义(P<0.05);T1诊断宫颈癌及宫颈癌前病变的特异性、准确度均高于高危型HPV-DNA、TCT,差异有统计学意义(P<0.05);T1准确度、敏感性均高于T2,差异有统计学意义(P<0.05)。结论 高危型HPV-DNA及TCT检测在筛查宫颈癌及宫颈癌前病变方面各具优势,而先行高危型HPV-DNA检测再行TCT检测筛选价值更高。
Abstract:
Objective To study the value of high-risk human papillomavirus-DNA (HPV-DNA) and liquid-based thin-layer cell detection system (TCT) in screening cervical carcinoma and cervical precancerous lesions. Methods 200 patients with cervical lesions admitted to our hospital from March 2016 to February 2019 were selected. All patients underwent high-risk HPV-DNA testing and TCT testing. The high-risk HPV-DNA and TCT single-test were performed first, followed by joint testing: T1 (first high-risk HPV-DNA, then TCT), T2 (first TCT, then high-risk HPV-DNA). The pathological examination results were followed up, and the pathological examination results were regarded as "gold standard". The sensitivity, specificity and accuracy of each detection method were evaluated. Results In this study, 168 cases (chronic cervicitis) and 32 cases (CINI grade and above) were confirmed by histopathological examination, including 16 cases of CINI, 15 cases of CINII~III, and 1 case of invasive carcinoma. High-risk HPV-DNA detection the sensitivity of cervical precancerous lesions and cervical carcinoma was higher than that of TCT and T2. The specificity and accuracy were lower than TCT, T2 and T1,the difference was statistically significant (P<0.05). T1 diagnosis of cervical cancer and cervical precancerous lesions the specificity and accuracy were higher than those of high-risk HPV-DNA and TCT,the difference was statistically significant (P<0.05). The accuracy and sensitivity of T1 were higher than T2,the difference was statistically significant (P<0.05).Conclusion The high-risk HPV-DNA and TCT tests have advantages in screening cervical carcinoma and cervical precancerous lesions, and the high-risk HPV-DNA test has a higher value for TCT detection.

参考文献/References:

[1]师晓艳,雷侠.宫颈液基细胞学检查与高危型HPV检测用于宫颈癌前病变并发感染早期筛查的对比研究[J].中国性科学,2017,26(1):33-35. [2]朱琳.TCT、HPV-DNA分型联合阴道镜检测在宫颈病变筛查中的作用[J].中国妇幼保健,2017,32(14):3375-3378. [3]郑蓓佳,陈琪,顾华敏.高危型人乳头状瘤病毒联合TCT检测在宫颈癌早期筛查中的应用[J].中国卫生检验杂志,2016,26(2):247-249. [4]任士霞,李连芹.高危型HPV检测与TCT筛查宫颈癌准确性比较[J].齐鲁医学杂志,2017,32(6):669-672. [5]王登海,陈忠萍,居峰,等.TCT联合HPV-DNA及端粒酶检测在宫颈癌前病变评估中的应用价值[J].检验医学与临床,2017,14(21):65-66. [6]喻垚,郭变琴,罗光丽,等.液基细胞学与高危型HPV-DNA联合检测在宫颈病变筛查中的意义[J].检验医学与临床,2015, 12(11):1550-1551. [7]帕提曼·米吉提,唐努尔·阿不力米提,古扎丽努尔·阿不力孜.高危型HPV检测联合TCT用于宫颈癌筛查及其危险因素分析[J].中国地方病防治杂志,2016,31(5):577. [8]高华玲,尹德娥,杜杰,等.TCT和HR-HPV-DNA检测在宫颈癌和癌前病变筛查中的临床价值[J].标记免疫分析与临床,2017,24(10):1115-1118. [9]陶志梅,潘敏,俞美娟,等.高危型人乳头瘤病毒感染联合液基薄层细胞检测对宫颈癌及宫颈癌前病变筛查与随访的临床意义[J].中华医院感染学杂志,2017,27(10):2340-2343. [10]熊炜,陈萰.TCT和HPV-DNA联合检测在宫颈癌及癌前病变筛查中的应用价值[J].中国计划生育和妇产科,2015,7(12):45-47.

相似文献/References:

[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
 LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Journal of Medical Information,2018,31(22):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
 XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Journal of Medical Information,2018,31(22):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[3]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
 HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Journal of Medical Information,2018,31(22):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[4]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
 XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Journal of Medical Information,2018,31(22):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[5]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
 YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Journal of Medical Information,2018,31(22):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[6]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
 WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Journal of Medical Information,2018,31(22):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[7]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
 NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(22):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[8]吴晓玲,周桂华.miR-187在宫颈癌中的表达与临床病理关系的研究[J].医学信息,2018,31(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
 WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Journal of Medical Information,2018,31(22):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[9]夏为书,彭莉贞,钟清玲.我国宫颈癌患者配偶生活质量评价的研究现状[J].医学信息,2018,31(23):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
 XIA Wei-shu,PENG Li-zhen,ZHONG Qing-ling.Research Status of Spouse Quality of Life Evaluation of Cervical Cancer Patients in China[J].Journal of Medical Information,2018,31(22):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
[10]邢 均.全身麻醉联合硬膜外麻醉在宫颈癌手术中的应用及效果评价[J].医学信息,2019,32(01):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
 XING Jun.Application and Evaluation of General Anesthesia Combined with Epidural Anesthesia in[J].Journal of Medical Information,2019,32(22):122.[doi:10.3969/j.issn.1006-1959.2019.01.037]
[11]穆红茹.电子阴道镜下定位活检在宫颈病变诊断中的应用价值[J].医学信息,2022,35(01):178.[doi:10.3969/j.issn.1006-1959.2022.01.045]
 MU Hong-ru.Application Value of Localization Biopsy Under Electronic Colposcopy in Diagnosis of Cervical Lesions[J].Journal of Medical Information,2022,35(22):178.[doi:10.3969/j.issn.1006-1959.2022.01.045]
[12]见永康,吴泽俊,庄雅丽.宫颈癌筛查联合阴道镜活检防治宫颈癌前病变的价值研究[J].医学信息,2023,36(16):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
 JIAN Yong-kang,WU Ze-jun,ZHUANG Ya-li.Study on the Value of Cervical Cancer Screening Combined with Colposcopy Biopsy in the Prevention and Treatment of Cervical Precancerous Lesions[J].Journal of Medical Information,2023,36(22):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]

更新日期/Last Update: 2019-11-15